HF
Therapeutic Areas
Kesmalea Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Undisclosed Oncology Program(s) | Oncology | Preclinical |
| Undisclosed CNS Program(s) | Central Nervous System Disorders | Preclinical |
Leadership Team at Kesmalea Therapeutics
RJ
Robert Johnson
Chief Executive Officer
MF
Mark Fox
Finance Director
CW
Claire Walshe
VP Research & Early Development